These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15620562)

  • 1. Tiered pricing of vaccines: a win-win-win situation, not a subsidy.
    Plahte J
    Lancet Infect Dis; 2005 Jan; 5(1):58-63. PubMed ID: 15620562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global perspectives on vaccine financing.
    Berman S; Giffin RB
    Expert Rev Vaccines; 2004 Oct; 3(5):557-62. PubMed ID: 15485335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries.
    Moon S; Jambert E; Childs M; von Schoen-Angerer T
    Global Health; 2011 Oct; 7():39. PubMed ID: 21992405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
    Peny JM; Gleizes O; Covilard JP
    Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytics for vaccine economics and pricing: insights and observations.
    Robbins MJ; Jacobson SH
    Expert Rev Vaccines; 2015 Apr; 14(4):605-16. PubMed ID: 25435003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons learned in shaping vaccine markets in low-income countries: a review of the vaccine market segment supported by the GAVI Alliance.
    Gilchrist SA; Nanni A
    Health Policy Plan; 2013 Dec; 28(8):838-46. PubMed ID: 23174880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strengthening vaccination policies in Latin America: an evidence-based approach.
    Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
    Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can we defeat meningococcal disease in low and middle income countries?
    Greenwood B; Chiarot E; MacLennan CA; O'Ryan M
    Vaccine; 2012 May; 30 Suppl 2():B63-6. PubMed ID: 22607901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tiered Pricing and Alternative Mechanisms for Equitative Access to Vaccines in Latin America: A Narrative Review of the Literature.
    Arango-Luque A; Yucumá D; Castañeda CE; Espin J; Becerra-Posada F
    Value Health Reg Issues; 2024 Jul; 42():100981. PubMed ID: 38677063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines as a global imperative--a business perspective.
    Stéphenne J
    Health Aff (Millwood); 2011 Jun; 30(6):1042-8. PubMed ID: 21653955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mechanics and effects of European reference pricing for vaccines in Germany according to §130a Abs. 2 SGB V: an analysis using the example of influenza vaccines].
    Barth J; Hammerschmidt T; Vollmar J; Bierbaum M; Schöffski O
    Gesundheitswesen; 2014 Apr; 76(4):e7-e13. PubMed ID: 24081570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demand forecasting for preventive AIDS vaccines: economic and policy dimensions.
    Hecht R; Gandhi G
    Pharmacoeconomics; 2008; 26(8):679-97. PubMed ID: 18620461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing pediatric vaccine formularies and pricing pediatric combination vaccines using operations research models and algorithms.
    Jacobson SH; Sewell EC; Allwine DA; Medina EA; Weniger BG
    Expert Rev Vaccines; 2003 Feb; 2(1):15-9. PubMed ID: 12901593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mixed integer programming model for vaccine pricing within a group purchasing organization.
    Yu Z; Keskinocak P; Orenstein WA; Toktay LB
    Vaccine; 2024 Mar; 42(8):1892-1898. PubMed ID: 37977944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tiered co-payments, pricing, and demand in reference price markets for pharmaceuticals.
    Herr A; Suppliet M
    J Health Econ; 2017 Dec; 56():19-29. PubMed ID: 28964941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost analysis of producing vaccines in developing countries.
    Munira SL; Hendriks JT; Atmosukarto II; Friede MH; Carter LM; Butler JRG; Clements ACA
    Vaccine; 2019 Feb; 37(9):1245-1251. PubMed ID: 30651198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How Should the World Pay for a Coronavirus Disease (COVID-19) Vaccine?
    Towse A; Chalkidou K; Firth I; Kettler H; Silverman R
    Value Health; 2021 May; 24(5):625-631. PubMed ID: 33933230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccines at what price?
    Stephens DS; Ahmed R; Orenstein WA
    Vaccine; 2014 Feb; 32(9):1029-30. PubMed ID: 24412350
    [No Abstract]   [Full Text] [Related]  

  • 19. Variation in provider vaccine purchase prices and payer reimbursement.
    Freed GL; Cowan AE; Gregory S; Clark SJ
    Pediatrics; 2008 Dec; 122(6):1325-31. PubMed ID: 19047253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose versus multi-dose vaccine vials for immunization programmes in developing countries.
    Drain PK; Nelson CM; Lloyd JS
    Bull World Health Organ; 2003; 81(10):726-31. PubMed ID: 14758432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.